GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Short-Term Debt

Syntara (ASX:SNT) Short-Term Debt : A$0.45 Mil (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Syntara Short-Term Debt?

Syntara's Short-Term Debt for the quarter that ended in Dec. 2023 was A$0.45 Mil.

Syntara's quarterly Short-Term Debt declined from Dec. 2022 (A$2.36 Mil) to Jun. 2023 (A$0.00 Mil) but then increased from Jun. 2023 (A$0.00 Mil) to Dec. 2023 (A$0.45 Mil).

Syntara Short-Term Debt Historical Data

The historical data trend for Syntara's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Short-Term Debt Chart

Syntara Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Syntara Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.27 - 2.36 - 0.45

Syntara Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Syntara Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Syntara's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Syntara (ASX:SNT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Short-Term Debt
Comparable Companies
ASX:EOF ASX:ECS ASX:RGT ASX:IVX ASX:AGH ASX:IDT ASX:MVP ASX:LGP ASX:EXL ASX:BP8 XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
UUDA:Germany
Address
20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086
Website
https://www.pharmaxis.com.au
Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.